Repligen Corporation (RGEN) Announces Conference Call of Second Quarter Fiscal Year 2010 Results Thursday, November 5th, 10:00 a.m. EST
10/29/2009 10:46:59 AM
More...
|
Repligen Corporation (RGEN) Licenses Potential Treatment for Spinal Muscular Atrophy; Conference Call Scheduled for Friday, October 23 at 8:30 a.m. EDT
10/23/2009 9:04:27 AM
More...
|
Repligen Corporation (RGEN) Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
10/19/2009 11:28:48 AM
More...
|
Repligen Corporation (RGEN) Announces Identification of Drug Target for Friedreich's Ataxia Study Published in the September 25, 2009 Issue of Chemistry & Biology
9/25/2009 7:33:22 AM
More...
|
Repligen Corporation (RGEN) to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT
9/2/2009 9:04:40 AM
More...
|
Repligen Corporation (RGEN) Announces Conference Call of First Quarter Fiscal Year 2010 Results
7/30/2009 9:08:24 AM
More...
|
Repligen Corporation (RGEN) Reports Fourth Quarter and Fiscal Year 2009 Financial Results
6/11/2009 11:20:36 AM
More...
|
Repligen Corporation (RGEN) Licenses Patent Rights for Treatment of Bipolar Disorder
3/31/2009 10:47:33 AM
More...
|
Repligen Corporation (RGEN) Announces ISO 9001:2000 Certification
2/12/2009 6:43:54 AM
More...
|
Repligen Corporation (RGEN) Reports Third Quarter Fiscal Year 2009 Financial Results
2/5/2009 10:00:19 AM
More...
|
|